(Q34934934)

5 August 2017

1 reference

title

Novel insulins: expanding options in diabetes management (English)

1 reference

5 August 2017

1

John E Gerich

1 reference

PubMed ID

12361817

5 August 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

American Journal of Medicine

5 August 2017

1 reference

5 August 2017

113

1 reference

5 August 2017

4

1 reference

5 August 2017

308-316

1 reference

The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus

5 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Control of blood sugar in insulin-dependent diabetes: comparison of an artificial endocrine pancreas, continuous subcutaneous insulin infusion, and intensified conventional insulin therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Importance of Timing of Preprandial Subcutaneous Insulin Administration in the Management of Diabetes Mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

The importance of the time interval between insulin injection and breakfast in determining postprandial glycaemic control--a comparison between human and porcine insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Physiological insulin replacement in type 1 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Insulin analogues and their potential in the management of diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Inhaled human insulin treatment in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Altering the association properties of insulin by amino acid replacement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Bioavailability and bioeffectiveness of subcutaneous human insulin and two of its analogs--LysB28ProB29-human insulin and AspB10LysB28ProB29-human insulin--assessed in a conscious pig model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Effectiveness of postprandial Humalog in toddlers with diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Comparison of subcutaneous soluble human insulin and insulin analogues (AspB9, GluB27; AspB10; AspB28) on meal-related plasma glucose excursions in type I diabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Improved mealtime treatment of diabetes mellitus using an insulin analogue. Multicenter Insulin Lispro Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Insulin lispro in CSII: results of a double-blind crossover study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Insulin lispro (Lys(B28), Pro(B29) in the treatment of diabetes during the fasting month of Ramadan. Ramadan Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Meal composition is a determinant of lispro-induced hypoglycemia in IDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Direct comparison of insulin lispro and aspart shows small differences in plasma insulin profiles after subcutaneous injection in type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Time-action profile of inhaled insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Preliminary study of the efficacy of insulin aerosol delivered by oral inhalation in diabetic patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

7 January 2021

Insulin Pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Insulin analogues: new agents for improving glycemic control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Clinical pharmacology of human insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

Basal activity profiles of NPH and [Nepsilon-palmitoyl Lys (B29)] human insulins in subjects with IDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901176-2

10.1016/S0002-9343(02)01176-2

7 January 2021

Identifiers

DOI

1 reference

5 August 2017

1 reference

PubMed ID

12361817